Home
/ Lyell
/ Competitors

Lyell Competitors and Similar CompaniesClear all

Lyell's competitors and similar companies include Jounce Therapeutics, Arvinas, NovoCure and Agenus.

	Lyell Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.	Jounce Therapeutics Jounce Therapeutics is a clinical-stage immunotherapy company.	Arvinas Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases.	NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.	Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.
Founding Date	Founding Date 2018	Founding Date 2013	Founding Date N/A	Founding Date 2000	Founding Date 1994
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech oncology platform therapy	Tags Healthcare Technology healthtech oncology platform therapy	Tags Healthcare Technology drug development oncology pharma platform therapy	Tags Healthcare biotech medical devices oncology platform therapy	Tags Healthcare biotech clinical research drug development oncology pharma
Locations	Locations South San Francisco, US HQ Bothell, US Seattle, US	Locations Cambridge, US HQ	Locations New Haven, US HQ	Locations Saint Helier, JE HQ München, DE Haifa, IL Tokyo, JP Root, CH Malvern, US New York, US see more	Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US
Employees	Employees 188	Employees 1302% increase	Employees 13329% increase	Employees 1,453	Employees 38927% decrease
Valuation ($)	Valuation ($) 312.3 m	Valuation ($) 101.6 m	Valuation ($) 1.7 b	Valuation ($) 1.7 b	Valuation ($) 105.1 m
Financial
Revenue (est.)	Revenue (est.) $130k (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $78.5m (FY, 2023)	Revenue (est.) $509.3m (FY, 2023)	Revenue (est.) $156.3m (FY, 2023)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $128.3m (FY, 2023)	Cost of goods $3.1m (FY, 2023)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $381.1m (FY, 2023)	Gross profit $153.2m (FY, 2023)
Net income	Net income ($234.6m) (FY, 2023)	Net income ($50.9m) (FY, 2022)	Net income ($367.3m) (FY, 2023)	Net income ($207m) (FY, 2023)	Net income ($257.4m) (FY, 2023)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 103m	Total funding raised $ 111.6m	Total funding raised N/A	Total funding raised $ 171.1m